Pass ACRP ACRP-CP PDF Dumps Recently Updated 127 Questions [Q15-Q40]

Pass ACRP ACRP-CP PDF Dumps | Recently Updated 127 Questions

Updated Test Engine to Practice ACRP-CP Dumps & Practice Exam

NEW QUESTION # 15
A protocol inclusion criterion requires the serum magnesium at screening to be within the normal range. After the subject received IP, the CRC discovers the subject's screening magnesium level was below the normal range and the sub-investigator marked the lab sheet as not clinically significant. Which of the following should be done FIRST?

• A. Notify the sponsor.
• B. Notify the regulatory authority.
• C. Notify the subject.
• D. Withdraw the subject.

Answer: A

Explanation:
When a protocol deviation is identified, especially one involving inclusion criteria, the sponsor must be notified immediately. The sponsor will assess the deviation and determine whether the subject can continue in the study. Early notification ensures appropriate action and compliance with protocol and regulatory guidelines.
This answer aligns with GCP principles that mandate sponsor notification in case of protocol deviations, especially when they may impact participant safety or data integrity.
"Any deviation from the protocol that affects subject eligibility must be reported to the sponsor immediately for evaluation and guidance." Objectives:
* Maintain adherence to protocol inclusion criteria.
* Report deviations promptly for safety assessment.

NEW QUESTION # 16
During a monitoring visit, a CRA notices that a piece of equipment required for the study needs to be serviced. Who is responsible for addressing this problem?

• A. CRC
• B. CRA
• C. PI
• D. Sponsor

Answer: C

Explanation:
The Principal Investigator (PI) is responsible for ensuring that all equipment used in the clinical trial is properly maintained and serviced. If a monitor (CRA) identifies equipment that needs servicing, the PI must take immediate action to ensure the equipment is in working order to maintain the quality and integrity of the study data.
GCP guidelines emphasize the PI's responsibility to ensure that all equipment used in the study is functional, properly calibrated, and serviced as needed.
"The PI is responsible for maintaining the functionality and calibration of study-related equipment to ensure accurate data collection." Objectives:
Maintain equipment functionality to ensure data accuracy.
Ensure proper maintenance as part of site management.

NEW QUESTION # 17
A sponsor wants a new clinical trial to be reviewed at regular intervals for progress, safety, and endpoint evaluation, and make recommendations to continue, modify, or stop the trial. How should they proceed?

• A. Conduct routine investigators' meetings
• B. Draft a CAPA plan
• C. Establish a DSMB/IDMC
• D. Develop a monitoring plan

Answer: C

Explanation:
A Data Safety Monitoring Board (DSMB) or Independent Data Monitoring Committee (IDMC) is established to review ongoing trial data at regular intervals. The DSMB evaluates safety, progress, and efficacy endpoints and makes recommendations to continue, modify, or terminate the study based on interim data. This independent oversight helps ensure participant safety and data integrity throughout the trial.
GCP guidelines recommend forming a DSMB for studies that involve high risks or long durations, ensuring continuous safety monitoring.
"The DSMB is responsible for the periodic review of accumulating data and providing recommendations regarding trial continuation, modification, or termination." Objectives:
* Ensure ongoing safety evaluation.
* Facilitate objective decisions on trial continuation.

NEW QUESTION # 18
When designing a clinical trial, why is it important to define the study population?

• A. To determine where to conduct the study
• B. To support the study objectives
• C. To determine the study objectives
• D. To support subject recruitment to the study

Answer: B

Explanation:
Defining the study population is crucial because it ensures that the trial targets the appropriate group for evaluating the investigational product (IP). A well-defined population supports the study objectives by providing reliable and interpretable data that can address the research questions.
GCP guidelines emphasize the need for a clearly defined study population to ensure the generalizability and accuracy of trial results.
"The study population must be clearly defined to ensure that the trial data are relevant and applicable to the intended patient group." Objectives:
* Enhance the scientific validity of clinical trial outcomes.
* Support the accurate interpretation of efficacy and safety data.

NEW QUESTION # 19
Who is responsible to ensure training for key staff members unable to attend the site initiation visit?

• A. Investigator
• B. Monitor
• C. Sponsor
• D. Coordinator

Answer: A

Explanation:
The Principal Investigator (PI) is responsible for ensuring that all site staff involved in the study are adequately trained, even if they were unable to attend the Site Initiation Visit (SIV). This responsibility includes organizing training sessions or providing relevant training materials to maintain consistency and compliance with study protocols.
According to GCP guidelines, the PI must ensure that all staff members involved in the trial are adequately informed and trained on their specific responsibilities.
"The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions." Objectives:
* Maintain consistent training for all clinical staff.
* Ensure compliance with study procedures.

NEW QUESTION # 20
Confidentiality and privacy rules for protection of human subjects at research sites are determined by the:

• A. Sponsor
• B. Applicable regulatory authorities
• C. Applicable site SOPs
• D. PI

Answer: B

Explanation:
The confidentiality and privacy rules protecting human subjects in clinical research are established by applicable regulatory authorities, such as the FDA or EMA, and must be followed by all research sites. These regulations ensure that participants' personal data are handled securely and ethically.
GCP guidelines mandate compliance with local, national, and international regulations regarding data confidentiality and privacy.
"Confidentiality and privacy protections are determined by applicable regulatory authorities and must be adhered to by all study sites." Objectives:
* Protect participant privacy.
* Ensure compliance with data protection regulations.

NEW QUESTION # 21
An investigator participating in a multicenter clinical trial has had 2 of the 4 subjects admitted to the emergency room for life-threatening infections. The investigator made the decision to stop treatment with IP and test for infections in the remaining subjects. What are the NEXT steps the investigator should take?

• A. Add the risk of infection to the ICF and submit to the IRB/IEC for review.
• B. Notify the sponsor of the change in study plan and submit the deviation to the IRB/IEC for review.
• C. Update the IB to add the risk of infection and submit to the sponsor for approval.
• D. Discontinue current subjects from the study and monitor subjects for any anticipated safety events.

Answer: B

Explanation:
The investigator must promptly notify the sponsor about the observed safety concerns and the decision to stop the IP administration. This constitutes a protocol deviation that must be reported tothe IRB/IEC for ethical oversight. It is essential to document the deviation accurately and seek guidance on whether to continue or modify the study procedures.
GCP guidelines require that significant deviations impacting participant safety be reported to both the sponsor and the IRB/IEC for appropriate review and action.
"Significant safety-related deviations must be reported promptly to the sponsor and IRB/IEC to ensure proper oversight and participant protection." Objectives:
Ensure prompt reporting of safety concerns.
Maintain compliance with ethical oversight requirements.

NEW QUESTION # 22
An interim analysis is conducted during a clinical trial. To review the results, the sponsor assigns:

• A. Investigators participating in the trial.
• B. Regulatory authority expert advisors.
• C. Executive board members.
• D. Independent qualified individuals.

Answer: D

Explanation:
Interim analysis should be reviewed by independent qualified individuals, such as members of a Data Safety Monitoring Board (DSMB) or Independent Data Monitoring Committee (IDMC). This ensures that the analysis is unbiased and that decisions regarding continuation, modification, or termination of the trial are made objectively.
GCP guidelines emphasize that interim data should be reviewed by an independent committee to prevent bias and ensure participant safety.
"Interim analyses should be conducted by independent experts to maintain objectivity and safeguard trial integrity." Objectives:
* Maintain impartiality during interim analysis.
* Ensure unbiased decision-making regarding trial continuation.

NEW QUESTION # 23
While consenting a potential subject, a coordinator discovered the subject could not read. Under what conditions can this potential subject be enrolled?

• A. Get an impartial witness involved in consenting this person.
• B. There are no circumstances under which this person can be enrolled.
• C. Have the Principal Investigator consent the person.
• D. Locate a translator and have them work with the person.

Answer: A

Explanation:
When a participant cannot read, an impartial witness must be present during the consent process. The witness ensures that the information is accurately presented and that the subject's consent is truly informed. The witness must sign the consent form to attest that the subject understands the information.
GCP guidelines require the use of an impartial witness during the informed consent process for individuals who are illiterate or visually impaired.
"Informed consent must involve an impartial witness when the subject cannot read, ensuring the consent process is conducted ethically." Objectives:
* Maintain ethical standards during consent.
* Protect the rights of participants with literacy challenges.

NEW QUESTION # 24
The PI did not record the relationship to IP in the medical chart when assessing an adverse event. The CRC noticed the omission and brought it to the PI's attention. How should this be addressed?

• A. The PI should notify the monitor.
• B. The CRC should amend the medical chart.
• C. The PI should amend the medical chart.
• D. The CRC should write a note to file.

Answer: C

Explanation:
The PI is responsible for ensuring accurate documentation of adverse events (AEs) in the medical chart, including their relationship to the investigational product (IP). If an omission is identified, the PI must correct it by making a dated and signed amendment to maintain data accuracy and completeness.
GCP guidelines state that the PI must maintain accurate and complete records, including the assessment of the relationship between AEs and the IP.
"The investigator must document the assessment of the relationship between the AE and the investigational product to ensure accurate clinical records." Objectives:
* Maintain accuracy in adverse event documentation.
* Ensure data integrity through appropriate corrections.

NEW QUESTION # 25
All of the following are examples of what monitors review EXCEPT:

• A. Documentation in the participant's medical record of study drug administration.
• B. The signed ICF retained in the participant's study file.
• C. Potential patient medical records for eligibility prior to the informed consent process.
• D. Regulatory binder which includes copies of current certifications for all laboratories.

Answer: C

Explanation:
Monitors are responsible for reviewing documents that pertain to study conduct and data integrity,including regulatory binders, informed consent forms (ICFs), and documentation of study drug administration.
However, reviewing potential patient medical records for eligibility prior to the informed consent process is not part of a monitor's responsibilities, as this would violate patient confidentiality and GCP standards.
According to GCP guidelines, monitors should ensure compliance with the protocol and data integrity but should not access non-consented patient records.
"Monitors should verify that only enrolled and consented subjects' data are reviewed, ensuring compliance with privacy regulations." Objectives:
* Understand the scope of monitoring responsibilities.
* Protect patient confidentiality during the monitoring process.

NEW QUESTION # 26
Who is responsible for securing agreement from all involved parties to ensure direct access of all trial-related source documents?

• A. CRC
• B. CRO
• C. Investigator
• D. Sponsor

Answer: D

Explanation:
The sponsor is responsible for ensuring that agreements are in place with all involved parties (including investigators and institutions) to grant direct access to trial-related source documents. This is crucial for monitoring, auditing, and inspection purposes, ensuring transparency and compliance with regulatory requirements.
According to GCP guidelines, the sponsor must establish agreements to secure direct access to trial data for verification and compliance checks.
"The sponsor should ensure that agreements are in place to permit direct access to source data and documents for monitoring and inspection." Objectives:
* Maintain compliance with regulatory requirements.
* Facilitate data verification and quality assurance.

NEW QUESTION # 27
At a close-out visit, which document should be retained only at the site?

• A. IP accountability
• B. Treatment allocation
• C. Subject identification code list
• D. Final trial close-out monitoring report

Answer: C

Explanation:
The subject identification code list, which links the participant's unique code to their personal information, must be retained only at the site. This list ensures confidentiality and is necessary for identifying participants during follow-up. It is not shared with the sponsor to protect participant privacy.
GCP guidelines mandate that the subject identification code list remains at the site to ensure confidentiality and compliance with data protection regulations.
"The subject identification code list must be securely stored at the site to maintain participant confidentiality." Objectives:
* Safeguard participant confidentiality.
* Maintain compliance with data protection policies.

NEW QUESTION # 28
Per protocol, participants are scheduled to receive IP, which is calculated based on the participant's current weight. Unknown to the pharmacist, a participant recently lost 15 pounds and was overdosed as a result. What is the FIRST action the CRC must take to ensure the participant's safety?

• A. Notify the sponsor.
• B. Report a protocol deviation to the IRB/IEC.
• C. Notify the PI.
• D. Call the participant to return for an unscheduled visit.

Answer: C

Explanation:
The CRC's first responsibility is to immediately inform the Principal Investigator (PI), who is responsible for the participant's medical care. The PI will assess the situation, determine the potential risk, and initiate appropriate clinical actions to ensure the participant's safety. This may include medical evaluation or adjusting the dosing regimen.
According to GCP guidelines, any issue that may affect participant safety should be promptly communicated to the PI to ensure appropriate medical management.
"The investigator must be informed immediately of any events that could compromise participant safety, allowing for prompt clinical decision-making." Objectives:
* Ensure rapid response to dosing errors.
* Maintain participant safety as a priority.

NEW QUESTION # 29
Which one of the following is a primary objective of a Phase III study of a new IP?

• A. To establish the safety profile
• B. To establish dose information
• C. To show superiority over another treatment
• D. To demonstrate or confirm therapeutic benefit

Answer: D

Explanation:
Phase III clinical trials primarily aim to demonstrate or confirm the therapeutic benefit of a new investigational product (IP) compared to standard treatments or placebo. These trials are typically larger and are designed to provide robust evidence of efficacy and further evaluate safety.
According to GCP guidelines, Phase III trials focus on confirming the therapeutic efficacy of the IP in a larger population.
"Phase III trials aim to confirm the therapeutic benefit and safety of the investigational product compared to existing treatments." Objectives:
* Confirm therapeutic efficacy.
* Provide comprehensive safety data.

NEW QUESTION # 30
A study sponsor approaches a facility about participating in their research study. The study sponsor requires use of social media as its sole method of recruitment. The site knows their institutional IRB/IEC does not approve of social media recruiting. How should the site respond?

• A. Decline the study.
• B. Use a central IRB/IEC.
• C. Rely on the sponsor to notify the IRB/IEC.
• D. Recruit for the study without use of social media.

Answer: A

Explanation:
If the IRB/IEC has a policy that does not permit social media recruiting, the site must adhere to these regulations. Proceeding with a method not approved by the IRB/IEC would violate compliance requirements, so declining the study is the correct course of action.
The answer aligns with IRB/IEC regulations that prioritize ethical and compliant recruitment methods.
"Sites must follow the recruitment methods approved by their IRB/IEC to maintain compliance and ethical standards." Objectives:
* Adhering to ethical recruitment practices.
* Maintaining compliance with IRB/IEC policies.

NEW QUESTION # 31
An impartial witness should be present during the entire informed consent discussion when:

• A. An interpreter is translating the consent form for a subject.
• B. A legally acceptable representative is unable to read.
• C. A parent/guardian is consenting for a minor subject.
• D. A subject has been determined to be vulnerable.

Answer: B

Explanation:
An impartial witness is required when a legally acceptable representative (LAR) or the subject themselves cannot read. The witness ensures that the information is presented accurately and that the consent process is conducted ethically. The witness also signs the consent form to confirm that the subject or representative understands the study details.
GCP guidelines require an impartial witness to be present to confirm that the consent information is correctly conveyed and understood when the subject or LAR cannot read.
"An impartial witness is required when the subject or legally acceptable representative is unable to read, ensuring the consent process is transparent and ethically sound." Objectives:
* Protect the rights of individuals with literacy challenges.
* Maintain ethical standards in the consent process.

NEW QUESTION # 32
The inclusion and exclusion criteria are in place so all subjects are:

• A. Medically appropriate and protected from ethical vulnerability.
• B. Patients with the disease under study and will not have any adverse events.
• C. Ethically vulnerable and patients with the disease under study.
• D. Healthy and willing to complete the clinical trial.

Answer: A

Explanation:
Inclusion and exclusion criteria are designed to ensure that participants are medically appropriate for the study and are not ethically vulnerable. This reduces risks to subjects and ensures that the collected data accurately reflects the target population.
The answer follows GCP principles that emphasize participant safety and data validity through well-defined inclusion/exclusion criteria.
"Inclusion and exclusion criteria are crucial for ensuring the safety of participants and the scientific validity of study results." Objectives:
* Ensuring participant safety.
* Maintaining ethical standards in clinical research.

NEW QUESTION # 33
When determining whether a protocol deviation (PD) is reportable to the IRB/IEC, the PI should take into consideration whether the:

• A. PD affected participant safety.
• B. PD affected participant recruitment.
• C. Sponsor approved the PD.
• D. Participant verbally agreed to the PD.

Answer: A

Explanation:
The primary factor in determining whether a protocol deviation should be reported to the IRB/IEC is whether the deviation impacts participant safety or the integrity of the study data. Any deviation that could pose a risk to participants must be reported promptly to ensure ongoing ethical oversight.
GCP guidelines mandate reporting of any protocol deviations that affect safety or data integrity to the IRB
/IEC.
"Protocol deviations that impact the safety of participants or the integrity of the study must be reported to the IRB/IEC." Objectives:
* Maintain participant safety.
* Ensure regulatory compliance through prompt reporting.

NEW QUESTION # 34
A PI is reviewing the CRF for a recent subject visit and notices the participant's heart rate and temperature are not recorded. Which of the following study documentation practices was neglected?

• A. Attributable
• B. Contemporaneous
• C. Complete
• D. Original

Answer: C

Explanation:
The missing data indicates a lack of completeness in the study documentation. Completeness is a fundamental requirement in clinical trials, as all necessary information must be recorded accurately and in full. Missing vital signs such as heart rate and temperature can compromise the validity of the data and affect the study's outcomes.
GCP guidelines state that all data collected during the study must be complete, accurate, and consistent with source documents.
"Clinical trial documentation must be complete, containing all data as required by the protocol toensure data integrity." Objectives:
* Ensure comprehensive data recording.
* Maintain accuracy and completeness in study records.

NEW QUESTION # 35
Which of the following is a conflict of interest for a PI conducting a study?

• A. A PI who receives payment for the study
• B. A PI who is a key opinion leader, writes the protocol
• C. A PI that votes on the IRB/IEC approval of the protocol
• D. A PI that presents at an investigator meeting

Answer: C

Explanation:
A Principal Investigator (PI) who is involved in voting on the IRB/IEC approval of their own protocol is considered to have a conflict of interest. The IRB/IEC must be independent and impartial when reviewing research proposals. Allowing the PI to vote on their own study compromises the ethical review process. To maintain unbiased decision-making, PIs must recuse themselves from such votes.
GCP guidelines emphasize the importance of avoiding conflicts of interest in the IRB/IEC decision-making process to maintain objectivity and ethical standards.
"A PI should not participate in voting or decision-making processes regarding the approval of their own study to avoid conflicts of interest." Objectives:
* Maintain impartiality in ethical review.
* Prevent conflicts of interest during IRB/IEC processes.

NEW QUESTION # 36
After the completion or termination of a clinical trial, who should store the enrollment log?

• A. PI
• B. CRO
• C. Sponsor
• D. Regulatory authority

Answer: A

Explanation:
The Principal Investigator (PI) is responsible for maintaining and securely storing essential documents, including the enrollment log, after the completion or termination of a clinical trial. This ensures that all participant-related records are retained for audit or inspection as per regulatory requirements.
This answer is consistent with GCP guidelines, which specify that the PI is accountable for retaining essential trial documents at the study site.
"The investigator should maintain records of trial participants, including the enrollment log, as part of the essential documents for trial conduct." Objectives:
* Maintain data integrity and compliance with record-keeping requirements.
* Ensure secure and accessible storage of participant information.

NEW QUESTION # 37
A root cause analysis should be:

• A. Written by the investigator.
• B. Specific to a clinical trial.
• C. Validated before use in a CAPA.
• D. Focused on issues of non-compliance.

Answer: D

Explanation:
Root cause analysis (RCA) is a systematic process aimed at identifying the underlying reasons for non- compliance or errors in clinical trials. The purpose of RCA is to understand why a problem occurred so that corrective and preventive actions (CAPA) can be implemented effectively. Focusing on issues of non- compliance ensures that the study adheres to GCP and regulatory requirements.
GCP guidelines recommend performing a root cause analysis when deviations or non-compliance are identified to develop effective CAPA plans.
"Root cause analysis focuses on identifying non-compliance issues to implement corrective and preventive measures effectively." Objectives:
* Address non-compliance systematically.
* Develop effective CAPA plans.

NEW QUESTION # 38
A clinical trial is conducted to test the effect of an investigational drug on cholesterol levels. Statistical analysis will be performed to:

• A. Reject the alternative hypothesis that the drug has no effect on cholesterol levels.
• B. Fail to reject the alternative hypothesis that the drug has an effect on cholesterol levels.
• C. Reject the null hypothesis that the drug has no effect on cholesterol levels.
• D. Fail to reject the null hypothesis that the drug has an effect on cholesterol levels.

Answer: C

Explanation:
The purpose of statistical analysis in a clinical trial is to evaluate whether the data supports rejecting the null hypothesis, which typically states that there is no effect or difference. If the analysis finds a statistically significant result, the null hypothesis is rejected, indicating that the investigational drug has an effect on cholesterol levels.
The answer follows statistical principles in clinical trials, where the null hypothesis is rejected if evidence shows a significant difference or effect.
"In hypothesis testing, rejecting the null hypothesis indicates that the treatment effect is statistically significant." Objectives:
* Understand hypothesis testing in clinical research.
* Interpret statistical outcomes accurately.

NEW QUESTION # 39
Which of the following documents is maintained by a PI to ensure compliance with sponsor requirements?

• A. A monitoring report that identifies deviation from the approved protocol.
• B. Training records of site personnel on study protocol, and their study-related duties and functions.
• C. Regulatory submission of protocol and accompanying documents to relevant regulatory authority.
• D. A monitoring plan that is tailored to the specific human subject protection and data integrity risks of the trial.

Answer: B

NEW QUESTION # 40
......

ACRP ACRP-CP Dumps Cover Real Exam Questions: https://www.itexamreview.com/ACRP-CP-exam-dumps.html

Dumps Collection ACRP-CP Test Engine Dumps Training With 127 Questions: https://drive.google.com/open?id=1IyVxtBzyKLG0LtBl3HraKHF7HYtSCJlq